UroGen Pharma Ltd | ARS: Annual Report to Security Holders
UroGen Pharma Ltd | DEF 14A: Definitive information statements
UroGen Pharma Ltd | DEFA14A: Others
UroGen Pharma Ltd | SC 13G: Statement of acquisition of beneficial ownership by individuals-Cowen Financial Products LLC(4.36%),Cowen and Company, LLC(1.21%)
UroGen Pharma Ltd | SC 13G: Statement of acquisition of beneficial ownership by individuals-Point72 Asset Management, L.P.(6.2%),Point72 Capital Advisors, Inc.(6.2%), etc.
UroGen Pharma Ltd | 8-K: Current report
UroGen Pharma Ltd | 424B5: Prospectus
UroGen Pharma Ltd | 424B5: Prospectus
UroGen Pharma Ltd | 8-K: Current report
UroGen Pharma Ltd | 4: Statement of changes in beneficial ownership of securities-Officer Schoenberg Mark
UroGen Pharma Ltd | 144: Notice of proposed sale of securities pursuant to Rule 144
UroGen Pharma Ltd | 10-Q: Quarterly report
UroGen Pharma Ltd | 8-K: UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
UroGen Pharma Ltd | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.6%)
UroGen Pharma Ltd | 10-K/A: Annual report (Amendment)
UroGen Pharma Ltd | 4: Statement of changes in beneficial ownership of securities-Officer Schoenberg Mark
UroGen Pharma Ltd | 144: Notice of proposed sale of securities pursuant to Rule 144
UroGen Pharma Ltd | 10-K: Annual report
UroGen Pharma Ltd | 8-K: Current report
UroGen Pharma Ltd | 8-K: Current report
No Data